Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
Fda updates sits at the center of this dementia and brain health question.
Recent research and clinical evidence continue to highlight serious health risks associated with anticholinergic medications, drugs that millions of Americans take daily for conditions ranging from allergies and incontinence to depression and Parkinson’s disease. While a specific recent FDA warning update with that exact framing has not been formally announced, the medical community is increasingly unified in alerting patients and physicians to the dangers these medications pose—particularly for older adults and those at risk for cognitive decline. The concern is significant enough that major medical organizations like the American Geriatrics Society now recommend avoiding anticholinergic medications altogether in seniors, reflecting a dramatic shift in how the medical establishment views drugs that were once considered routine treatments. The gravity of this issue becomes clear when you consider the scope: these medications are prescribed so frequently that if the estimate of widespread use is accurate, tens of millions of people could be exposed to elevated risks of cardiovascular disease, physical decline, and dementia.
A patient taking diphenhydramine for allergies, for example, may not realize they’re using an anticholinergic drug at all—and they certainly may not know that recent 2024 research links such medications to a 71% higher risk of cardiovascular disease in high-dose users. For individuals already concerned about brain health or family history of dementia, this emerging evidence represents a critical consideration when managing chronic conditions. The situation reflects a larger pattern in medicine: drugs approved as safe decades ago are being re-evaluated in light of newer, larger studies with longer follow-up periods. In this case, the accumulating body of evidence has become impossible to ignore.
Table of Contents
- What Are Anticholinergic Drugs and Why Are They So Widely Used?
- The Cardiovascular and Physical Decline Risks New Research Reveals
- The Dementia Connection and Brain Health Implications
- Why Alternative Options and Medication Reviews Are Essential
- The Challenge of Recognizing Anticholinergic Side Effects and Drug Interactions
- What the American Geriatrics Society Recommends
- What Patients and Families Should Do Now
- Conclusion
What Are Anticholinergic Drugs and Why Are They So Widely Used?
Anticholinergic medications work by blocking acetylcholine, a neurotransmitter crucial for memory, learning, and muscle control. This mechanism of action makes these drugs useful for treating various conditions: antihistamines like diphenhydramine (Benadryl) reduce allergy symptoms, antidepressants like amitriptyline and paroxetine ease depression and anxiety, and medications like oxybutynin and tolterodine manage overactive bladder. The problem is that while blocking acetylcholine helps with the target symptom, it also affects the brain and other parts of the body in ways we’re only now fully understanding through large-scale research. Eight of the most commonly prescribed anticholinergics are atropine, amitriptyline, doxepin, paroxetine, chlorpheniramine, diphenhydramine, oxybutynin, and tolterodine.
These medications are so deeply embedded in standard medical practice that patients may be taking them without realizing they’re anticholinergics at all. A person prescribed an antidepressant for anxiety, for instance, might not connect that medication to their bladder medication or their over-the-counter allergy remedy—yet if these drugs accumulate in the system, the combined anticholinergic burden can increase health risks substantially. The prevalence of these medications speaks to their utility in treating common, bothersome conditions. Yet this widespread use combined with new evidence creates a public health challenge: millions of people may need to reconsider their medications, a process that requires time, physician engagement, and viable alternatives.
The Cardiovascular and Physical Decline Risks New Research Reveals
A landmark 2024 study from Karolinska Institutet, published in BMC Medicine, found that people taking the highest doses of anticholinergic drugs had a 71% higher risk of developing cardiovascular disease compared to those not using these medications. This wasn’t a small or short-term study—it represents a significant finding from rigorous research that tracked real-world outcomes. The risk appears dose-dependent, meaning that higher cumulative exposure to anticholinergics correlates with greater cardiovascular danger, yet many patients and even some physicians may not adjust prescribing practices based on this risk. Beyond cardiovascular concerns, another large study following over 4,000 older adults for more than eight years discovered that higher exposure to anticholinergic medications was associated with faster physical decline in walking speed and grip strength.
This finding is particularly important for older adults who already face age-related physical changes; anticholinergic medications appear to accelerate this natural decline, increasing fall risk and loss of independence. A patient taking anticholinergics might notice they’re moving more slowly or feel weaker, attributing these changes to aging itself rather than recognizing medication as a contributing factor. One important limitation of these findings is that they don’t yet clarify which patients face the greatest risk or whether some anticholinergics carry more danger than others. Individual health status, genetics, and concurrent medications all likely play a role, yet the research suggests caution across the board.
The Dementia Connection and Brain Health Implications
Perhaps the most concerning finding for readers of a dementia-focused publication is the emerging evidence linking anticholinergic medications to increased dementia risk. Research from 2024-2025, including studies published through PMC and JAMA Internal Medicine, confirms associations between specific anticholinergic classes—particularly antidepressants and bladder medications—and higher incidence of dementia in longitudinal studies. Since acetylcholine plays a central role in memory and cognition, blocking it chronically makes biological sense as a potential dementia risk factor, and the epidemiological data increasingly supports this concern. What makes this research particularly relevant for dementia prevention efforts is that many anticholinergic prescriptions are given to older adults—the very population most vulnerable to cognitive decline.
A person taking tolterodine for overactive bladder or amitriptyline for depression in their 60s or 70s may be inadvertently increasing their dementia risk during the critical decade when cognitive reserve becomes increasingly important. The timing and duration of use likely matter, though research is still clarifying these relationships. The challenge in responding to this evidence is that for some patients, anticholinergic medications provide genuine symptom relief or treat conditions that would otherwise impact quality of life. Stopping them abruptly may not be advisable either. This creates a clinical situation where patients and doctors must carefully weigh the benefits of treating present symptoms against the long-term risks of cognitive decline.
Why Alternative Options and Medication Reviews Are Essential
Given the emerging risks, one of the most actionable steps any person over 65—or anyone with a family history of dementia—can take is to request a comprehensive medication review from their physician or pharmacist. Many effective alternatives to anticholinergic drugs exist. For overactive bladder, for example, options include pelvic floor physical therapy, behavioral interventions, or other medication classes. For depression and anxiety, SSRIs like sertraline have fewer anticholinergic properties than older tricyclic antidepressants. For allergies, newer antihistamines like cetirizine or loratadine have minimal anticholinergic effects compared to diphenhydramine. The tradeoff is often one of convenience versus safety.
Diphenhydramine, for instance, works quickly and is available without a prescription—qualities that made it a favorite for decades. But safer alternatives, while perhaps requiring more thoughtful dosing or different timing, are available. A medication review might reveal that a patient has been prescribed an anticholinergic for a condition that could be managed through non-drug approaches, or that a safer alternative was never explored. For patients taking multiple anticholinergic medications—a common situation—even switching one or two to safer alternatives can meaningfully reduce overall anticholinergic burden. Physicians increasingly have tools to assess anticholinergic burden and consider deprescribing—the systematic reduction or elimination of medications that may no longer be necessary or that pose unacceptable risks. This is not about abruptly stopping medications, but rather about thoughtful substitution and gradual adjustment under medical supervision.
The Challenge of Recognizing Anticholinergic Side Effects and Drug Interactions
Many patients taking anticholinergic medications experience side effects they don’t connect to the drug. Dry mouth, constipation, blurred vision, dizziness, and confusion are common anticholinergic effects that are often attributed to aging or other causes. More concerning are cognitive effects: some patients report subtle memory problems, difficulty concentrating, or increased confusion—symptoms that can masquerade as early cognitive decline or be dismissed as normal aging. This creates a diagnostic and therapeutic problem: a patient experiencing cognitive changes may be evaluated for dementia when actually their medication is contributing to the problem. An important limitation in current medical practice is that many patients—and some physicians—are not aware of which medications they’re taking that have anticholinergic properties. An older adult prescribed an antidepressant, an antihistamine, and a bladder medication from three different doctors may not realize these drugs have overlapping mechanisms that could amplify side effects and risks.
The cumulative anticholinergic burden from multiple medications is often not calculated or discussed, leaving patients unaware that their total exposure is high. Additionally, anticholinergic medications can interact with other drugs and conditions in complex ways. In patients with cognitive impairment, they may worsen confusion. In those with urinary retention or constipation, they exacerbate these problems. Patients with glaucoma need to avoid certain anticholinergics entirely. These interactions underscore why a comprehensive medication review is so valuable.
What the American Geriatrics Society Recommends
The American Geriatrics Society, a leading organization of physicians specializing in older adult care, now explicitly recommends avoiding anticholinergic medications in older adults as part of their Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. This is a dramatic recommendation—essentially stating that for the older population, the risks of these medications generally outweigh the benefits.
The guidance acknowledges that in rare cases, an anticholinergic might still be necessary, but the default approach should be seeking alternatives. This recommendation carries weight because it represents a consensus among specialists who treat older adults daily and see firsthand the cognitive and physical consequences of medication accumulation. For a patient or family member reading this, it means that if an older relative is taking an anticholinergic medication, there’s good reason to initiate a conversation with their doctor about alternatives.
What Patients and Families Should Do Now
The path forward for individuals already taking anticholinergic medications is not to panic or stop medications abruptly, but to engage actively with their healthcare providers. Schedule a medication review appointment with your physician or pharmacist—many can assess your anticholinergic burden using validated tools. Bring a list of all medications, including over-the-counter drugs and supplements. Ask explicitly about whether each medication has anticholinergic properties and whether safer alternatives are available.
If you’re taking multiple anticholinergics, discuss deprescribing strategies that could reduce your total burden. Looking forward, the medical field is likely to see continued pressure to move away from anticholinergic medications in favor of alternatives with better safety profiles, especially for aging populations. Emerging treatments for conditions like overactive bladder, depression, and Parkinson’s disease may eventually reduce reliance on anticholinergics altogether. In the meantime, patients have agency: being informed about these risks and actively partnering with healthcare providers to review medication choices is one of the most powerful steps available to protect long-term brain health and physical function.
Conclusion
While a specific FDA warning update with the exact framing mentioned may not have been formally announced, the underlying reality is just as important: substantial scientific evidence now demonstrates that anticholinergic medications carry significant risks for cardiovascular disease, physical decline, and cognitive impairment—risks that the medical community is increasingly acknowledging and acting upon. For the millions of Americans taking these drugs, often without realizing they’re anticholinergics, this information represents both a challenge and an opportunity to reassess medication choices with their physicians. The most important next step is awareness combined with action.
If you or a loved one is taking medications for allergies, depression, incontinence, or other common conditions, ask your doctor whether these medications are anticholinergics and whether safer alternatives exist. A medication review takes time but can meaningfully reduce future dementia risk and improve overall health outcomes. In an era when dementia prevention is increasingly recognized as possible through modifiable risk factors, medication optimization stands as one of the most concrete steps available.
You Might Also Like
- Indiana University Study Links Anticholinergic Drugs to 64 Percent Higher Dementia Risk
- FDA Warns of Brain Bleeding Risk With New Class of Dementia Drugs
- FDA Issues Warning About Common Sleep Aid Linked to Dementia Risk
For more, see National Institute on Aging.
